Imaging Evaluation of Central Nervous Autoimmune Diseases

Shandong University

Status: Unknown

Conditions: NMO Spectrum Disorder; MS (Multiple Sclerosis)

Treatments: Diagnostic Test: MRI

Study type: Observational

Funder types: Other

Identifiers

NCT04822623

2020SDUCRCC019

Details and patient eligibility

About

Multiple sclerosis (MS) is the most common demyelinating disease of the central nervous system and the most common cause of non traumatic disability in young and middle-aged people. Neuromyelitis optica spectrum disease (nmosd) is an independent disease different from Ms. the pathogenesis and the mode of brain and spinal cord injury are different from MS, and the prognosis and optimal treatment are different. It is difficult to distinguish the two diseases in the early stage. Early diagnosis and treatment of the two diseases can greatly improve the quality of life of patients. Therefore, it is an urgent problem to clarify the difference between MS and nmosd injury patterns and to find sensitive imaging markers for early clinical intervention. With the continuous progress of computer aided diagnosis (CAD), it is more and more widely used in medicine, which is expected to help solve the above problems.

The purpose of this study is to create a neuroimmune disease evaluation database based on image data. By combining brain and spinal cord imaging, and based on Zhang quantum space learning computer-aided technology, we can achieve accurate segmentation of MS and nmosd brain and spinal cord lesions, analyze the evolution characteristics of the disease at different time points, and screen the imaging indexes related to clinical scores combined with clinical and laboratory indexes Objective: to determine the different prognosis and its influencing factors at the clinical, imaging and molecular levels, and establish the model for predicting disease progression and prognosis, so as to provide the basis for early identification and assistance in guiding treatment and judging prognosis.

Clinical information was collected: age, gender, course of disease, MMSE, EDSS disability score, nine hole test, 25 foot walking test. Assess the patient's information processing ability. Blood samples were collected. Imaging examination was performed. The patients were followed up regularly.

Enrollment: 300 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. 18-65 years old;
2. Nmosd was diagnosed according to wingerchuk standard revised in 2015, MS was diagnosed according to McDonald standard revised in 2017, and 100 normal people were diagnosed;
3. In the acute stage, within 1 month of the onset or stable stage, there was no GD enhanced lesion on MRI, and EDSS score had no significant change within 6 months, which was more than 1 month from the last attack;
4. MRI examination was complete: baseline, 6 months, 1 year, 2 years;
5. Sign informed consent.

Exclusion criteria

1. The course of disease was more than 30 years;
2. History of brain injury or spinal cord injury;
3. History of central nervous system infection or immunodeficiency syndrome;
4. HBV, HCV patients, syphilis, HIV-1, HIV-2 patients;
5. Suffering from mental illness;
6. Pregnant and lactating women or patients planning to conceive within one year;
7. Unable to cooperate to complete the follow-up due to geographical or other reasons;
8. Patients also participated in other randomized controlled trials.

Trial design

300 participants in 3 patient groups

MS

Treatment:

Diagnostic Test: MRI

NMOSD

Treatment:

Diagnostic Test: MRI

Control

Treatment:

Diagnostic Test: MRI